API | ins365

ins365 Report issue

Small molecule Experimental

AACT ChEMBL Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW

Chemistry

SMILES: O=c1ccn([C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@H]3O[C@@H](n4ccc(=O)[nH]c4=O)[C@H](O)[C@@H]3O)[C@@H](O)[C@H]2O)c(=O)[nH]1
InChIKey: NMLMACJWHPHKGR-NCOIDOBVSA-N
Mol. Mass: 790.31
ALogP: -4.19 Partition coefficient
ChEMBL Molecules:

diquafosol

diquafosol tetrasodium

More Chemistry

Pharmacology

Mechanisms of Action:
- P2Y purinoceptor 1 (Homo sapiens) ^UniProt
- P2Y purinoceptor 2 (Homo sapiens) ^UniProt
- P2Y purinoceptor 4 (Homo sapiens) ^UniProt
- P2Y purinoceptor 6 (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

de-089 | diquafosol | diquafosol sodium | diquafosol tetrasodium | diuridine 5'-(pentahydrogen tetraphosphate) tetrasodium salt | ins365 | ins 365 | ins-365

Organizations (4)

Research & Development (4)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (3)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (3)

Dry Eye Syndromes (Phase 3)

Keratoconjunctivitis Sicca (Phase 3)

Photorefractive Keratectomy (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 13
# of Trial Organizations: 4

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue